sb 203580 has been researched along with sb 225002 in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (sb 225002) | Trials (sb 225002) | Recent Studies (post-2010) (sb 225002) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 92 | 0 | 73 |
| Protein | Taxonomy | sb 203580 (IC50) | sb 225002 (IC50) |
|---|---|---|---|
| C-X-C chemokine receptor type 1 | Homo sapiens (human) | 0.022 | |
| C-X-C chemokine receptor type 2 | Homo sapiens (human) | 0.0623 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, D; Xu, J; Zhao, Y | 1 |
1 other study(ies) available for sb 203580 and sb 225002
| Article | Year |
|---|---|
Activation of CXCL5-CXCR2 axis promotes proliferation and accelerates G1 to S phase transition of papillary thyroid carcinoma cells and activates JNK and p38 pathways.
Topics: Animals; Anthracenes; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL5; G1 Phase Cell Cycle Checkpoints; Humans; Imidazoles; MAP Kinase Signaling System; Mice; Mice, Nude; Phenylurea Compounds; Phosphorylation; Pyridines; Receptors, Interleukin-8B; Recombinant Proteins; Thyroid Cancer, Papillary; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2019 |